95 related articles for article (PubMed ID: 3127608)
1. The cost-effectiveness of cervical cancer screening for low-income elderly women.
Mandelblatt JS; Fahs MC
JAMA; 1988 Apr 22-29; 259(16):2409-13. PubMed ID: 3127608
[TBL] [Abstract][Full Text] [Related]
2. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.
Goldie SJ; Weinstein MC; Kuntz KM; Freedberg KA
Ann Intern Med; 1999 Jan; 130(2):97-107. PubMed ID: 10068381
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing.
Brown AD; Garber AM
JAMA; 1999 Jan; 281(4):347-53. PubMed ID: 9929088
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of cervical cancer screening for the elderly.
Fahs MC; Mandelblatt J; Schechter C; Muller C
Ann Intern Med; 1992 Sep; 117(6):520-7. PubMed ID: 1503355
[TBL] [Abstract][Full Text] [Related]
5. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of cervical cancer screening: comparison of screening policies.
van den Akker-van Marle ME; van Ballegooijen M; van Oortmarssen GJ; Boer R; Habbema JD
J Natl Cancer Inst; 2002 Feb; 94(3):193-204. PubMed ID: 11830609
[TBL] [Abstract][Full Text] [Related]
7. Gynecological care of elderly women. Another look at Papanicolaou smear testing.
Mandelblatt J; Gopaul I; Wistreich M
JAMA; 1986 Jul; 256(3):367-71. PubMed ID: 3723723
[TBL] [Abstract][Full Text] [Related]
8. Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening.
Myers ER; McCrory DC; Subramanian S; McCall N; Nanda K; Datta S; Matchar DB
Obstet Gynecol; 2000 Nov; 96(5 Pt 1):645-52. PubMed ID: 11042294
[TBL] [Abstract][Full Text] [Related]
9. Modeling cost-effectiveness of cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
[TBL] [Abstract][Full Text] [Related]
10. Impact of increasing Papanicolaou test sensitivity and compliance: a modeled cost and outcomes analysis.
Montz FJ; Farber FL; Bristow RE; Cornelison T
Obstet Gynecol; 2001 May; 97(5 Pt 1):781-8. PubMed ID: 11339934
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of methods to enhance sensitivity of Papanicolaou testing.
Sedlacek TV
JAMA; 1999 Oct; 282(15):1419-20. PubMed ID: 10535424
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of methods to enhance sensitivity of Papanicolaou testing.
Leidy NK; Brown R; Luce B; Sheets E
JAMA; 1999 Oct; 282(15):1419; author reply 1420. PubMed ID: 10535423
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.
Kulasingam SL; Myers ER; Lawson HW; McConnell KJ; Kerlikowske K; Melnikow J; Washington AE; Sawaya GF
Obstet Gynecol; 2006 Feb; 107(2 Pt 1):321-8. PubMed ID: 16449119
[TBL] [Abstract][Full Text] [Related]
14. Does cost-effectiveness analysis make a difference? Lessons from Pap smears. Symposium.
Hagen MD; Garber AM; Goldie SJ; Lafata JE; Mandelblatt J; Meltzer D; Neumann P; Siegel JE; Sox HC; Tsevat J
Med Decis Making; 2001; 21(4):307-23. PubMed ID: 11475387
[No Abstract] [Full Text] [Related]
15. Cost-effective policies for cervical cancer screening. An international review.
Fahs MC; Plichta SB; Mandelblatt JS
Pharmacoeconomics; 1996 Mar; 9(3):211-30. PubMed ID: 10160098
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
Vanni T; Luz PM; Grinsztejn B; Veloso VG; Foss A; Mesa-Frias M; Legood R
Int J Cancer; 2012 Jul; 131(2):E96-104. PubMed ID: 21964797
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cervical cancer screening and follow-up programs.
Celentano DD; deLissovoy G
Public Health Rev; 1989-1990; 17(2-3):173-240. PubMed ID: 2518819
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
19. An alternative cost effectiveness analysis of ThinPrep in the Australian setting.
Neville AM; Quinn MA
Aust N Z J Obstet Gynaecol; 2005 Aug; 45(4):289-94. PubMed ID: 16029294
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of cervical cytologic examination during pregnancy.
Carter PM; Coburn TC; Luszczak M
J Am Board Fam Pract; 1993; 6(6):537-45. PubMed ID: 8285092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
